Corcept Therapeutics (CORT) Misses Q1 EPS by 19c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $77.44 -5.48%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.30), $0.19 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $183.28 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.95-1.05 billion, versus the consensus of $0.93 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Fidelity National Information Services (FIS) PT Lowered to $35 at Raymond James
- SharkNinja (SN) PT Raised to $300 at Jefferies
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
